{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:15:35Z","timestamp":1787066135531,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Oncology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.oraloncology.2011.01.002","type":"journal-article","created":{"date-parts":[[2011,2,10]],"date-time":"2011-02-10T06:42:40Z","timestamp":1297320160000},"page":"185-190","source":"Crossref","is-referenced-by-count":115,"title":["Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I\u2013II study"],"prefix":"10.1016","volume":"47","author":[{"given":"Carla Ida","family":"Ripamonti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Cislaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Maniezzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 8","key":"10.1016\/j.oraloncology.2011.01.002_b0005","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.oraloncology.2011.01.002_b0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3959(98)00135-3","article-title":"The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials","volume":"78","author":"Fulfaro","year":"1998","journal-title":"Pain"},{"issue":"9","key":"10.1016\/j.oraloncology.2011.01.002_b0020","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.oraloncology.2011.01.002_b0025","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.oraloncology.2011.01.002_b0015","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.oraloncology.2011.01.002_b0030","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.oraloncology.2011.01.002_b0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC working party on leukaemia in adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.oraloncology.2011.01.002_b0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.oraloncology.2011.01.002_b0045","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.oraloncology.2011.01.002_b0050","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.oraloncology.2011.01.002_b0055","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.oraloncology.2011.01.002_b0060","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antiestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.oraloncology.2011.01.002_b0065","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.oraloncology.2011.01.002_b0070","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","article-title":"American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.oraloncology.2011.01.002_b0075","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.oraloncology.2011.01.002_b0080","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European myeloma network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.oraloncology.2011.01.002_b0085","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/JTO.0b013e3181b68e5a","article-title":"Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel","volume":"4","author":"De Marinis","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.oraloncology.2011.01.002_b0090","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.oraloncology.2011.01.002_b0095","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2006.12.006","article-title":"International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients","volume":"43","author":"Body","year":"2007","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.oraloncology.2011.01.002_b0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.oraloncology.2011.01.002_b0105","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.oraloncology.2011.01.002_b0110","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.oraloncology.2011.01.002_b0115","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","article-title":"Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy","volume":"65","author":"Wang","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"10.1016\/j.oraloncology.2011.01.002_b0120","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jebdp.2007.05.013","article-title":"Osteonecrosis of the jaw (ONJ) might explain the increased oral surgery risk in cancer patients treated with bisphosphonates","volume":"7","author":"Van den Wyngaert","year":"2007","journal-title":"J Evid Based Dent Pract"},{"issue":"3","key":"10.1016\/j.oraloncology.2011.01.002_b0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1359-6349(09)72055-5","article-title":"A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"7","author":"Henry","year":"2009","journal-title":"Eur J Cancer Suppl"},{"issue":"3","key":"10.1016\/j.oraloncology.2011.01.002_b0130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1359-6349(09)72028-2","article-title":"Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study","volume":"7","author":"Stopeck","year":"2009","journal-title":"Eur J Cancer Suppl"},{"issue":"10","key":"10.1016\/j.oraloncology.2011.01.002_b0135","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.oraloncology.2011.01.002_b0140","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00520-010-0882-1","article-title":"A systematic review of bisphosphonate osteonecrosis (BON) in cancer","volume":"18","author":"Migliorati","year":"2010","journal-title":"Support Care Cancer"},{"issue":"1\u20134","key":"10.1016\/j.oraloncology.2011.01.002_b0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000151371","article-title":"Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench","volume":"189","author":"Allen","year":"2009","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.oraloncology.2011.01.002_b0150","unstructured":"Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws. Lda J 2005;64(3):21\u20134."},{"key":"10.1016\/j.oraloncology.2011.01.002_b0155","doi-asserted-by":"crossref","unstructured":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65(3):369\u201376.","DOI":"10.1016\/j.joms.2006.11.003"},{"issue":"1","key":"10.1016\/j.oraloncology.2011.01.002_b0160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JOP.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"J Oncol Pract"},{"issue":"2","key":"10.1016\/j.oraloncology.2011.01.002_b0165","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2013May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.oraloncology.2011.01.002_b0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.oraloncology.2011.01.002_b0175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.oraloncology.2011.01.002_b0180","first-page":"3613","article-title":"Antibiotic prophylaxis before dental procedures can reduce ONJ incidence","volume":"110","author":"Montefusco","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"10.1016\/j.oraloncology.2011.01.002_b0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/0962935062000197083","article-title":"Ozone as Janus: this controversial gas can be either toxic or medically useful","volume":"13","author":"Bocci","year":"2004","journal-title":"Mediators Inflamm"},{"issue":"2","key":"10.1016\/j.oraloncology.2011.01.002_b0190","first-page":"4","article-title":"Experimental-morphological study of the anti-inflammatory action of ozone-perfluorane complex application","volume":"87","author":"Grigor\u2019ian","year":"2008","journal-title":"Stomatologiia (Mosk)"},{"issue":"6","key":"10.1016\/j.oraloncology.2011.01.002_b0195","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/01.scs.0000249350.59096.d0","article-title":"New therapeutic protocol in the treatment of avascular necrosis of the jaws","volume":"17","author":"Agrillo","year":"2006","journal-title":"J Craniofac Surg"},{"issue":"5","key":"10.1016\/j.oraloncology.2011.01.002_b0200","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/SCS.0b013e3181572609","article-title":"Ozone therapy in extractive surgery on patients treated with bisphosphonates","volume":"18","author":"Agrillo","year":"2007","journal-title":"J Craniofac Surg"},{"issue":"5","key":"10.1016\/j.oraloncology.2011.01.002_b0205","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/scs.0b013e31857261f","article-title":"Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis","volume":"18","author":"Agrillo","year":"2007","journal-title":"J Craniofac Surg"},{"issue":"9","key":"10.1016\/j.oraloncology.2011.01.002_b0210","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3324\/haematol.11096","article-title":"Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients","volume":"92","author":"Petrucci","year":"2007","journal-title":"Haematologica"},{"issue":"5 Suppl","key":"10.1016\/j.oraloncology.2011.01.002_b0215","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.joms.2009.01.009","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"10.1016\/j.oraloncology.2011.01.002_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1016\/j.oraloncology.2011.01.002_b0225","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2307\/2531294","article-title":"Confidence limits for probability of response in multistage phase II clinical trials","volume":"41","author":"Atkinson","year":"1985","journal-title":"Biometrics"}],"container-title":["Oral Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368837511000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368837511000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T08:56:34Z","timestamp":1559984194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368837511000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S1368837511000030"],"URL":"https:\/\/doi.org\/10.1016\/j.oraloncology.2011.01.002","relation":{},"ISSN":["1368-8375"],"issn-type":[{"value":"1368-8375","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}